Cellectis (CLLS) to Release Earnings on Monday

Cellectis (NASDAQ:CLLS - Get Free Report) is set to post its quarterly earnings results after the market closes on Monday, November 4th. Analysts expect Cellectis to post earnings of ($0.20) per share for the quarter.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.05. The business had revenue of $9.50 million for the quarter, compared to analysts' expectations of $6.00 million. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. On average, analysts expect Cellectis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cellectis Stock Down 2.2 %

Shares of CLLS traded down $0.04 during trading hours on Thursday, hitting $1.78. The company had a trading volume of 20,079 shares, compared to its average volume of 47,246. Cellectis has a one year low of $0.96 and a one year high of $3.77. The company's fifty day moving average price is $2.13 and its two-hundred day moving average price is $2.30. The company has a market capitalization of $98.94 million, a PE ratio of -1.45 and a beta of 3.09. The company has a current ratio of 1.92, a quick ratio of 1.92 and a debt-to-equity ratio of 0.39.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Cellectis in a report on Monday. They issued a "sell" rating on the stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.